Sweden

IRLAB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

IRLAB's Clinical Drug Candidate IRL752 Published in JPET

Lead Product(s): IRL752

Therapeutic Area: Neurology Product Name: IRL752

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls).

IRLAB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders

Lead Product(s): IRL752

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2020

Details:

The results from the clinical phase IIa study, now published, indicate that IRL752 has the potential to improve balance and reduce the risk of falls.

IRLAB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

IRLAB's IRL790 Receives New Name `mesdopetam'

Lead Product(s): Mesdopetam

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

WHO concluded that IRL790 is wholly unique in its mechanism of action and has, therefore, given IRL790 a new INN.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

IRLAB

IRLAB's Clinical Drug Candidate IRL752 Published in JPET

IRLAB

IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders

IRLAB

IRLAB's IRL790 Receives New Name `mesdopetam'